Research programme: covalent inhibitors - AurigeneAlternative Names: CDK7 inhibitor; KRAS inhibitor
Latest Information Update: 25 May 2016
At a glance
- Originator Aurigene Discovery Technologies
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase inhibitors; KRAS protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer